{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:59:06Z","timestamp":1794945546561,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CSL Behring"},{"DOI":"10.13039\/501100020480","name":"CSL Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020480","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and\/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP)\u2009\u2265\u20092\u2009mg\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    at baseline were randomized to receive clazakizumab (2.5\u2009mg, 5\u2009mg or 10\u2009mg,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200932 per dose group) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) every 4\u2009weeks. The primary endpoint was the change from baseline in hs-CRP to week 12, expressed as the geometric mean ratio. Clazakizumab treatment signficantly reduced serum hs-CRP concentrations at week 12 by 86%, 90% and 92% relative to placebo in patients randomized to 2.5\u2009mg, 5\u2009mg or 10\u2009mg clazakizumab, respectively (all\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001), meeting the primary outcome. With regard to secondary endpoints, clazakizumab treatment reduced serum fibrinogen, amyloid A, secretory phospholipase A2, and lipoprotein(a) concentrations, as well as increased mean serum albumin concentrations at 12 weeks, relative to placebo. The proportion of patients who achieved hs-CRP\u2009&lt;\u20092.0\u2009mg\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    was 79%, 82% and 79% in the 2.5\u2009mg, 5\u2009mg and 10\u2009mg clazakizumab groups, respectively, compared with 0% of placebo-treated patients. With regard to safety, no cases of sustained grade 3 or 4 thrombocytopenia or neutropenia were observed. Serious infections were seen with similar frequency in the placebo, clazakizumab 2.5\u2009mg and clazakizumab 5\u2009mg groups, but were numerically more frequent in the clazakizumab 10\u2009mg group. The results of this trial indicate that in patients receiving maintenance dialysis, clazakizumab reduced inflammatory biomarkers associated with cardiovascular events. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05485961\">NCT05485961<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-03043-1","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T11:01:17Z","timestamp":1716634877000},"page":"2328-2336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-0534","authenticated-orcid":false,"given":"Glenn M.","family":"Chertow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6064-0280","authenticated-orcid":false,"given":"Mark","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Velkoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-9125","authenticated-orcid":false,"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":false,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Mears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-4820","authenticated-orcid":false,"given":"Peter","family":"Stenvinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-7117","authenticated-orcid":false,"given":"Angela Yee-Moon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Tricoci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-1442","authenticated-orcid":false,"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"3043_CR1","unstructured":"USRDS. 2023 annual data report: epidemiology of kidney disease in the United States. usrds-adr.niddk.nih.gov\/2023\/introduction (2023)."},{"key":"3043_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey, A. S. et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84\u2013104 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"3043_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238\u2013248 (2005).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395\u20131407 (2009).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR5","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181\u20132192 (2011).","journal-title":"Lancet"},{"key":"3043_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836\u2013843 (2000).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR7","doi-asserted-by":"publisher","first-page":"106806","DOI":"10.1016\/j.vph.2020.106806","volume":"135","author":"GM Gager","year":"2020","unstructured":"Gager, G. M. et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. Vascul. Pharmacol. 135, 106806 (2020).","journal-title":"Vascul. Pharmacol."},{"key":"3043_CR8","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","volume":"72","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk JACC review topic of the week. J. Am. Coll. Cardiol. 72, 3320\u20133331 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3043_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/ki.2008.449","volume":"74","author":"RS Parekh","year":"2008","unstructured":"Parekh, R. S. et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int. 74, 1335\u20131342 (2008).","journal-title":"Kidney Int."},{"key":"3043_CR10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","unstructured":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium et al.The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 379, 1214\u20131224 (2012).","journal-title":"Lancet"},{"key":"3043_CR11","doi-asserted-by":"publisher","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","volume":"6","author":"C Held","year":"2017","unstructured":"Held, C. et al. Inflammatory biomarkers interleukin\u20106 and C\u2010reactive protein and outcomes in stable coronary heart disease: experiences from the stability (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J. Am. Hear. Assoc. 6, e005077 (2017).","journal-title":"J. Am. Hear. Assoc."},{"key":"3043_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR13","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Hear. J. 39, 3499\u20133507 (2018).","journal-title":"Eur. Hear. J."},{"key":"3043_CR14","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.2215\/CJN.00710111","volume":"6","author":"J Bazeley","year":"2011","unstructured":"Bazeley, J. et al. C-Reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 2452\u20132461 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"3043_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., B\u00f6hm, M. & Marx, N. Cardiovascular disease in chronic kidney disease. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"3043_CR16","doi-asserted-by":"publisher","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","volume":"33","author":"M Cozzolino","year":"2018","unstructured":"Cozzolino, M. et al. Cardiovascular disease in dialysis patients. Nephrol. Dial. Transplant. 33, iii28\u2013iii34 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"3043_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJM197403282901301","volume":"290","author":"A Lindner","year":"1974","unstructured":"Lindner, A., Charra, B., Sherrard, D. J. & Scribner, B. H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290, 697\u2013701 (1974).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5301\/ijao.5000411","volume":"38","author":"S Lichtenberg","year":"2015","unstructured":"Lichtenberg, S. et al. An intradialytic increase in serum interleukin-6 levels is associated with an increased mortality in hemodialysis patients. Int. J. Artif. Organs 38, 237\u2013243 (2015).","journal-title":"Int. J. Artif. Organs"},{"key":"3043_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11255-020-02461-7","volume":"52","author":"LV Thang","year":"2020","unstructured":"Thang, L. V. et al. Interleukin 6 is a better predictor of 5-year cardiovascular mortality than high-sensitivity C-reactive protein in hemodialysis patients using reused low-flux dialyzers. Int. Urol. Nephrol. 52, 1135\u20131142 (2020).","journal-title":"Int. Urol. Nephrol."},{"key":"3043_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.291.4.451","volume":"291","author":"Y Liu","year":"2004","unstructured":"Liu, Y. et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291, 451\u2013459 (2004).","journal-title":"JAMA"},{"key":"3043_CR21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","volume":"382","author":"S Bangalore","year":"2020","unstructured":"Bangalore, S. et al. Management of coronary disease in patients with advanced kidney disease. N. Engl. J. Med. 382, 1608\u20131618 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR22","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","volume":"43","author":"PM Ridker","year":"2022","unstructured":"Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P. & MacFadyen, J. G. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur. Hear. J. 43, 4832\u20134844 (2022).","journal-title":"Eur. Hear. J."},{"key":"3043_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jamacardio.2021.3079","volume":"6","author":"G Batra","year":"2021","unstructured":"Batra, G. et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA Cardiol. 6, 1445 (2021).","journal-title":"JAMA Cardiol."},{"key":"3043_CR24","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838\u20131847 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR25","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR26","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/bcp.15191","volume":"88","author":"AJ Cupido","year":"2022","unstructured":"Cupido, A. J. et al. Dissecting the IL\u20106 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R. Br. J. Clin. Pharmacol. 88, 2875\u20132884 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"3043_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02446-6","volume":"20","author":"MK Georgakis","year":"2022","unstructured":"Georgakis, M. K. et al. Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups. BMC Med. 20, 245 (2022).","journal-title":"BMC Med."},{"key":"3043_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41525-019-0097-4","volume":"4","author":"M Rosa","year":"2019","unstructured":"Rosa, M. et al. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. NPJ Genom. Med. 4, 23 (2019).","journal-title":"NPJ Genom. Med."},{"key":"3043_CR29","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 71, 2405\u20132414 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3043_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319\u2013328 (2018).","journal-title":"Lancet"},{"key":"3043_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199309303291404","volume":"329","author":"WF Owen","year":"1993","unstructured":"Owen, W. F., Lew, N. L., Liu, Y., Lowrie, E. G. & Lazarus, J. M. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N. Engl. J. Med. 329, 1001\u20131006 (1993).","journal-title":"N. Engl. J. Med."},{"key":"3043_CR32","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1046\/j.1523-1755.2000.00112.x","volume":"57","author":"JA Eustace","year":"2000","unstructured":"Eustace, J. A. et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int. 57, 2527\u20132538 (2000).","journal-title":"Kidney Int."},{"key":"3043_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.ajkd.2006.03.046","volume":"48","author":"JB Leon","year":"2006","unstructured":"Leon, J. B. et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am. J. Kidney Dis. 48, 28\u201336 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"3043_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ki.2012.75","volume":"82","author":"GA Kaysen","year":"2012","unstructured":"Kaysen, G. A. et al. The effect of frequent hemodialysis on nutrition and body composition: frequent hemodialysis network trial. Kidney Int. 82, 90\u201399 (2012).","journal-title":"Kidney Int."},{"key":"3043_CR35","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069 (2021).","journal-title":"Lancet"},{"key":"3043_CR36","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","volume":"117","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc. Res. 117, e138\u2013e140 (2021).","journal-title":"Cardiovasc. Res."},{"key":"3043_CR37","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.kint.2022.06.022","volume":"102","author":"LM Dember","year":"2022","unstructured":"Dember, L. M. et al. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney Int. 102, 1178\u20131187 (2022).","journal-title":"Kidney Int."},{"key":"3043_CR38","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"ME Weinblatt","year":"2015","unstructured":"Weinblatt, M. E. et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate\u2010to\u2010severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double\u2010blind, placebo\/active\u2010controlled, dose\u2010ranging study. Arthritis Rheumatol. 67, 2591\u20132600 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"3043_CR39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.39700","volume":"68","author":"PJ Mease","year":"2016","unstructured":"Mease, P. J. et al. The efficacy and safety of clazakizumab, an anti-interleukin\u20106 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 68, 2163\u20132173 (2016).","journal-title":"Arthritis Rheumatol."}],"updated-by":[{"DOI":"10.1038\/s41591-024-03156-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03043-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:08:38Z","timestamp":1724047718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03043-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03043-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03156-7","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03156-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M.C. has served on the Board of Directors of Satellite Healthcare, a nonprofit dialysis provider. His institution (Stanford University) has received a grant from the trial sponsor, CSL Behring. G.M.C. has served as Chair or Cochair of Trial Steering Committees with Akebia, AstraZeneca, CSL Behring, Sanifit and Vertex. He has served as an Advisor to Alexion, Applaud, Ardelyx, CalciMedica, Calico, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset, Renibus and Unicycive. He has served as Chair or Member of Data Safety Monitoring Boards for clinical trials sponsored by Bayer, Mineralys and ReCor. A.M.C., M.H., R.C., J.M. and P.T. are employees of and hold stock in CSL Behring. E.V. is an employee of CSL Limited. G.M.F. received research grants from NIH, Bayer, BMS, Novartis, Daxor, Merck, Cytokinetics and CSL Behring. He has acted as a consultant to Novartis, BMS, Cytokinetics, Innolife, Boehringer Ingelheim, Abbott, Sanofi, Regeneron, Myovant, Sequana, Windtree Therapeutics and Whiteswell, and has served on clinical endpoint committees\/data safety monitoring boards for Merck, Medtronic, EBR Systems, Rocket Pharma, V-Wave and LivaNova. B.F. has served in from CSL Behring. D.M.C. reports consultancy with Eli Lilly\/Boehringer Ingelheim, AstraZeneca, Allena Pharmaceuticals (DSMB), Gilead, Novo Nordisk, GSK, Medtronic, Merck, CSL Behring, Zogenix, Renalytix and LG Chemical. He has received research funding from Medtronic, Gilead; Novo Nordisk; Amgen, Boehringer Ingelheim\/Eli Lilly; and has held patents or royalties with UpToDate.com for authorship\/editorials on reviews. C.M.G. receives research and consulting support from CSL Behring. S.G.G. received research grant support (for example, steering committee or data and safety monitoring committee) and\/or speaker\/consulting honoraria (for example, advisory boards) from CSL Behring, Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CYTE Ltd., Daiichi Sankyo\/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A\/C, Pendopharm\/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals and Valeo Pharma and salary support\/honoraria from the Canadian Heart Failure Society, Canadian Heart Research Center and MD Primer, Canadian VIGOUR Center, Cleveland Clinic Coordinating Center for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\\CIUSSS Center-Ouest-de-l\u2019Ile-de-Montreal, New York University Clinical Coordinating Center, PERFUSE Research Institute, Peter Munk Cardiac Center Clinical Trials and Translation Unit, Ted Rogers Heart Center and TIMI Study Group (Brigham Health). M.J. has received support from CSL Behring. A.L. has received support from CSL Behring. R.M. has received institutional research payments from Abbott, Abiomed, Affluent Medical, Alleviant Medical, Amgen, AM Pharma, Arena, AstraZeneca, AtriCure, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, CERC, Chiesi, Cleerly Health, Concept Medical, Cytosorbents, Daiichi Sankyo, Duke, Element Science, Essential Medical, Faraday, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere, Medtelligence, Medtronic, MJH Healthcare, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi Cardia, PLx Pharma, Population Health Research Institute, Protembis, RecCor Medical, RenalPro, RM Global, Sanofi, Shockwave and Vivasure, Zoll. She received personal fees from Affluent Medical, Boehringer Ingelheim, Cardiovascular Research Foundation (CRF), Cordis, Daiichi Sankyo Brasil, E.R. Squibb Sons, Esperion Science\/Innovative Biopharma, Europa Group\/Boston Scientific, Gaffney Events, Educational Trust, Henry Ford Health Cardiology, Ionis Pharmaceuticals, Lilly and Company, MedCon International, Novartis, Novo Nordisk, PeerView Institute for Medical Education, TERUMO Europe N.V., Vectura, VoxMedia, WebMD, IQVIA, Radcliffe and TARSUS Cardiology. She received honoraria from the American Medical Association for her role as Associate Editor of <i>JAMA Cardiology<\/i>, ACC (BOT Member, SC Member CTR Program), and holds less than 1% equity in Elixir Medical, Stel. P.S. has received research support from AstraZeneca and Bayer. He has been a member of SAB for Baxter, FMC, Boehinger Mannheim, CSL, Alexion, GSK, lnvizius. D.C.W. has received honoraria\/consultancy fees and\/or speakers fees from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Eledon, Galderma, GSK, Gilead, Merck, Pharmacosmos, ProKidney, Tricida and Vifor. P.M.R. received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion, Novo Nordisk and the NHLBI; during the past 5\u2009years he has served as a consultant to Novartis, Flame, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Civi Biopharm, GSK, SOCAR, Novo Nordisk, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer Ingelheim and RTI; Zomagen, Cytokinetics, Horizon Therapeutics and Cardio Therapeutics. He has minority shareholder equity positions in Uppton, Bitterroot Bio and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR and the Baim Institute (Boston, MA). K.W.M. has received institutional and consulting funding from CSLB. M.W. has received research support from CSL through his institution, the Duke Clinical Research Institute, for the current study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}